See more : Genesis Park Acquisition Corp. (GNPK-UN) Income Statement Analysis – Financial Results
Complete financial analysis of Dr. Reddy’s Laboratories Limited (RDY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dr. Reddy’s Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Caisse Régionale de Crédit Agricole Mutuel de La Touraine et du Poitou Société Coopérative (CRTO.PA) Income Statement Analysis – Financial Results
- ShiFang Holding Limited (1831.HK) Income Statement Analysis – Financial Results
- Spring Valley Acquisition Corp. (SVSVU) Income Statement Analysis – Financial Results
- Bike24 Holding AG (BIKE.DE) Income Statement Analysis – Financial Results
- Oricon Enterprises Limited (ORICONENT.NS) Income Statement Analysis – Financial Results
Dr. Reddy's Laboratories Limited (RDY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.drreddys.com
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 279.16B | 245.88B | 214.39B | 189.72B | 174.60B | 153.85B | 142.03B | 140.81B | 154.71B | 148.19B | 132.17B | 116.27B | 96.74B | 74.69B | 70.28B | 69.44B | 50.01B | 65.25B | 24.33B | 19.47B | 20.12B | 18.02B | 16.60B | 10.94B |
| Cost of Revenue | 115.56B | 42.91B | 100.55B | 86.65B | 80.59B | 70.42B | 65.72B | 62.45B | 62.43B | 62.79B | 56.37B | 55.69B | 43.43B | 34.43B | 33.94B | 32.94B | 24.60B | 34.30B | 12.45B | 9.39B | 9.37B | 7.82B | 6.86B | 5.72B |
| Gross Profit | 163.61B | 202.97B | 113.84B | 103.08B | 94.01B | 83.43B | 76.30B | 78.36B | 92.28B | 85.40B | 75.80B | 60.58B | 53.31B | 40.26B | 36.34B | 36.50B | 25.41B | 30.95B | 11.88B | 10.09B | 10.76B | 10.20B | 9.74B | 5.22B |
| Gross Profit Ratio | 58.61% | 82.55% | 53.10% | 54.33% | 53.84% | 54.23% | 53.72% | 55.65% | 59.65% | 57.63% | 57.35% | 52.10% | 55.10% | 53.90% | 51.71% | 52.56% | 50.81% | 47.43% | 48.83% | 51.80% | 53.46% | 56.62% | 58.68% | 47.74% |
| Research & Development | 22.87B | 19.38B | 17.48B | 16.54B | 15.41B | 15.61B | 18.27B | 19.55B | 17.83B | 17.45B | 12.40B | 7.67B | 5.91B | 5.06B | 3.79B | 4.04B | 3.53B | 2.47B | 2.16B | 2.80B | 2.00B | 1.37B | 740.85M | 506.99M |
| General & Administrative | 0.00 | 46.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 59.47B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.20B | 105.93B | 62.08B | 54.56B | 50.13B | 48.89B | 46.91B | 46.37B | 45.70B | 42.59B | 38.78B | 33.58B | 28.87B | 23.69B | 22.51B | 21.02B | 15.18B | 14.08B | 8.05B | 6.81B | 6.58B | 5.01B | 3.66B | 2.81B |
| Other Expenses | -4.20B | -7.70B | -2.76B | -982.00M | -4.29B | -691.00M | -843.00M | -1.15B | -986.00M | -1.06B | -1.36B | -2.34B | -784.00M | -1.12B | -569.00M | 254.00M | 3.34B | 3.14B | 226.45M | 838.82M | 100.65M | 488.15M | 278.38M | 418.71M |
| Operating Expenses | 95.88B | 117.62B | 76.80B | 70.12B | 61.25B | 62.54B | 64.39B | 64.86B | 62.66B | 59.12B | 49.77B | 38.78B | 34.01B | 27.64B | 25.73B | 25.31B | 22.05B | 19.70B | 10.43B | 10.45B | 8.67B | 6.86B | 4.68B | 3.73B |
| Cost & Expenses | 211.44B | 160.52B | 177.35B | 156.76B | 141.84B | 132.96B | 130.11B | 127.31B | 125.09B | 121.90B | 106.14B | 94.47B | 77.45B | 62.07B | 59.67B | 58.25B | 46.65B | 54.00B | 22.88B | 19.84B | 18.04B | 14.68B | 11.54B | 9.45B |
| Interest Income | 2.28B | 1.18B | 3.08B | 2.62B | 888.00M | 2.28B | 540.00M | 558.00M | 1.40B | 1.06B | 1.09B | 900.00M | 377.00M | 173.00M | 369.00M | 482.00M | 1.60B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.71B | 1.43B | 958.00M | 970.00M | 983.00M | 1.16B | 788.00M | 634.00M | 826.00M | 1.09B | 1.27B | 1.02B | 1.07B | 362.00M | 372.00M | 1.67B | 1.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.84B | 12.64B | 11.82B | 12.80B | 12.47B | 12.19B | 11.71B | 11.28B | 10.25B | 8.10B | 7.11B | 5.55B | 5.21B | 4.15B | 4.16B | 3.81B | 6.20B | 3.02B | 1.57B | 1.31B | 1.13B | 1.01B | 945.26M | 892.60M |
| EBITDA | 88.42B | 74.43B | 47.74B | 45.71B | 41.79B | 31.87B | 23.74B | 24.55B | 40.18B | 35.16B | 33.14B | 22.49B | 20.33B | 16.82B | 6.59B | 1.49B | 7.31B | 14.27B | 2.71B | 1.02B | 2.83B | 4.35B | 6.01B | 2.38B |
| EBITDA Ratio | 31.67% | 44.24% | 24.55% | 25.75% | 28.37% | 15.34% | 8.39% | 9.59% | 19.15% | 17.74% | 19.70% | 19.34% | 21.02% | 16.90% | 21.61% | 22.33% | 16.79% | 23.67% | 11.13% | 4.24% | 14.09% | 22.62% | 33.95% | 21.17% |
| Operating Income | 67.73B | 96.28B | 40.82B | 36.06B | 37.06B | 20.89B | 11.92B | 13.50B | 29.62B | 26.29B | 26.03B | 21.11B | 18.25B | 12.63B | 2.01B | -2.83B | 3.36B | 11.25B | 1.45B | -366.46M | 2.08B | 3.34B | 5.06B | 1.49B |
| Operating Income Ratio | 24.26% | 39.16% | 19.04% | 19.01% | 21.22% | 13.58% | 8.39% | 9.59% | 19.15% | 17.74% | 19.70% | 18.16% | 18.87% | 16.91% | 2.86% | -4.08% | 6.71% | 17.24% | 5.94% | -1.88% | 10.36% | 18.52% | 30.47% | 13.59% |
| Total Other Income/Expenses | 4.14B | 3.34B | 2.82B | 4.04B | 2.04B | 1.56B | 2.42B | 1.16B | -2.48B | 1.88B | 574.00M | 1.41B | 214.00M | -186.00M | -7.99B | -15.44B | -493.72M | -725.88M | 446.53M | 107.40M | 465.35M | 572.90M | 9.11M | -426.12M |
| Income Before Tax | 71.87B | 60.49B | 32.30B | 28.32B | 18.03B | 22.44B | 14.34B | 14.65B | 27.14B | 28.16B | 26.61B | 21.68B | 18.47B | 12.44B | 2.05B | -4.00B | 3.44B | 10.53B | 1.89B | 107.03M | 2.55B | 3.92B | 5.07B | 1.06B |
| Income Before Tax Ratio | 25.74% | 24.60% | 15.06% | 14.93% | 10.33% | 14.59% | 10.10% | 10.41% | 17.54% | 19.00% | 20.13% | 18.64% | 19.09% | 16.66% | 2.92% | -5.75% | 6.88% | 16.13% | 7.78% | 0.55% | 12.65% | 21.75% | 30.53% | 9.69% |
| Income Tax Expense | 16.19B | 15.41B | 8.73B | 9.18B | -1.47B | 3.65B | 4.54B | 2.61B | 7.13B | 5.98B | 5.09B | 4.90B | 4.20B | 1.40B | 985.00M | 1.17B | -1.23B | 1.18B | 259.07M | -94.28M | 69.41M | 396.92M | 153.68M | 320.24M |
| Net Income | 55.68B | 45.07B | 23.57B | 17.24B | 19.50B | 18.80B | 9.81B | 12.04B | 20.01B | 22.18B | 21.51B | 16.78B | 14.26B | 11.04B | 1.07B | -5.17B | 4.68B | 9.35B | 1.63B | 211.27M | 2.48B | 3.52B | 4.92B | 739.28M |
| Net Income Ratio | 19.95% | 18.33% | 10.99% | 9.09% | 11.17% | 12.22% | 6.90% | 8.55% | 12.94% | 14.97% | 16.28% | 14.43% | 14.74% | 14.78% | 1.52% | -7.44% | 9.36% | 14.33% | 6.71% | 1.08% | 12.32% | 19.55% | 29.60% | 6.76% |
| EPS | 334.02 | 271.47 | 142.08 | 103.94 | 117.62 | 113.28 | 59.13 | 72.24 | 117.34 | 130.22 | 126.52 | 98.82 | 84.16 | 65.28 | 6.33 | -30.70 | 22.88 | 58.46 | 10.64 | 1.38 | 15.79 | 23.05 | 32.33 | 5.85 |
| EPS Diluted | 334.02 | 270.90 | 141.69 | 103.65 | 117.40 | 113.09 | 59.01 | 72.09 | 116.98 | 129.75 | 126.04 | 98.44 | 83.81 | 64.95 | 6.30 | -30.70 | 22.80 | 58.21 | 10.62 | 1.38 | 15.78 | 23.05 | 32.27 | 5.85 |
| Weighted Avg Shares Out | 166.71M | 166.03M | 165.88M | 165.84M | 165.76M | 165.92M | 165.85M | 166.65M | 170.55M | 170.31M | 170.04M | 169.78M | 169.47M | 169.13M | 168.71M | 168.35M | 168.08M | 158.55M | 153.09M | 153.04M | 153.03M | 153.03M | 152.06M | 126.36M |
| Weighted Avg Shares Out (Dil) | 166.71M | 166.38M | 166.34M | 166.32M | 166.08M | 166.20M | 166.19M | 167.00M | 171.07M | 170.93M | 170.70M | 170.43M | 170.18M | 169.97M | 169.62M | 168.35M | 168.69M | 159.26M | 153.40M | 153.12M | 153.10M | 153.03M | 152.30M | 126.36M |
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Dr. Reddy's (RDY), Kainomyx Sign Potential Deal for Malaria Drug
Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy
Dr. Reddy's (RDY) Q1 Earnings Miss Estimates, Revenues Beat
Dr. Reddy's Q1FY25 Financial Results
Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug
Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
Source: https://incomestatements.info
Category: Stock Reports